Showing results (71-80 of 140) with videos related to
Sort By:
Pageof 14
Leukemia & Lymphoma|February 1, 2011
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254Richard R Furman, Michael L Grossbard, Jeffrey L Johnson, et al.JAMA Oncology|February 23, 2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical TrialsSusan M O'Brien, Samantha Jaglowski, John C Byrd, et al.Cellular and Molecular Life Sciences : CMLS|April 9, 2025
Complementary approaches define the metabolic features that accompany Richter syndrome transformationGiulia Omezzolli, Andrea Iannello, Francesco E Vallone, et al.Leukemia & Lymphoma|April 16, 2014
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomabRebecca L Elstrom, Jia Ruan, Paul J Christos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesRanjana H Advani, Joseph J Buggy, Jeff P Sharman, et al.Hemasphere|November 15, 2019
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaSteven E Coutre, Ian W Flinn, Sven de Vos, et al.Clinical Pharmacology in Drug Development|August 27, 2022
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump InhibitorsShringi Sharma, Xavier Pepin, Harini Burri, et al.Blood|February 14, 2018
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceSusan O'Brien, Richard R Furman, Steven Coutre, et al.British Journal of Haematology|June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsJeffrey Jones, Anthony Mato, Steven Coutre, et al.Blood|February 26, 2017
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemiaLian Xu, Nicholas Tsakmaklis, Guang Yang, et al.Pageof 14